These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29089796)

  • 1. Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding.
    Srikanthan A; Mai H; Penner N; Amir E; Laupacis A; Sabharwal M; Chan KKW
    Curr Oncol; 2017 Oct; 24(5):295-301. PubMed ID: 29089796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the reasons for provincial discordance in cancer drug funding-a survey of policymakers.
    Srikanthan A; Penner N; Chan KKW; Sabharwal M; Grill A
    Curr Oncol; 2018 Aug; 25(4):257-261. PubMed ID: 30111966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Provincial elections and timing of cancer drug funding.
    Srikanthan A; Gill SS; Chan KK
    Curr Oncol; 2016 Jun; 23(3):154-63. PubMed ID: 27330343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of the Cancer Drug Funding Process in Canada.
    Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
    Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example.
    McDonald H; Charles C; Elit L; Gafni A
    J Mark Access Health Policy; 2016; 4():. PubMed ID: 27489586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study.
    Lexchin J
    BMJ Open; 2019 Jul; 9(7):e030750. PubMed ID: 31350254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of rarity on Canadian oncology health technology assessment and funding.
    Keech J; Dai WF; Trudeau M; Mercer RE; Naipaul R; Wright FC; Ferguson SE; Darling G; Gavura S; Eisen A; Kouroukis CT; Beca J; Chan KKW
    Int J Technol Assess Health Care; 2020 Aug; ():1-6. PubMed ID: 32779560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 9. Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).
    Masucci L; Beca J; Sabharwal M; Hoch JS
    Pharmacoecon Open; 2017 Dec; 1(4):255-263. PubMed ID: 29441502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
    Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C
    Front Pharmacol; 2019; 10():196. PubMed ID: 30983993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prioritization preferences of pan-Canadian Oncology Drug Review members and the Canadian public: a stated-preferences comparison.
    Skedgel C
    Curr Oncol; 2016 Oct; 23(5):322-328. PubMed ID: 27803596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disparity in public funding of systemic therapy for metastatic renal cell carcinoma in Canada.
    Jackson EB; Hotte SJ
    Can Urol Assoc J; 2022 Nov; 16(11):E516-E522. PubMed ID: 35704937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meaningful patient representation informing Canada's cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review.
    Hoch JS; Brown MB; McMahon C; Nanson J; Rozmovits L
    Curr Oncol; 2014 Oct; 21(5):263-6. PubMed ID: 25302034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
    Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
    Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review.
    Rocchi A; Chabot I; Glennie J
    Clinicoecon Outcomes Res; 2015; 7():287-98. PubMed ID: 26082654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
    Meyers DE; Jenei K; Chisamore TM; Gyawali B
    JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review.
    Niraula S
    Cancer; 2019 Sep; 125(18):3100-3103. PubMed ID: 31154671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The timing of drug funding announcements relative to elections: a case study involving dementia medications.
    Gill SS; Gupta N; Bell CM; Rochon PA; Austin PC; Laupacis A
    PLoS One; 2013; 8(2):e56921. PubMed ID: 23460820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs.
    Saluja R; Jiao T; Koshy L; Cheung M; Chan KKW
    Curr Oncol; 2021 Jan; 28(1):606-618. PubMed ID: 33498460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.
    Lexchin J
    BMJ Open; 2017 Oct; 7(10):e018372. PubMed ID: 29061631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.